EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rare genetic variation in fibronectin 1 (FN1) protects against APOEε4 in Alzheimer’s disease

Prabesh Bhattarai, Tamil Iniyan Gunasekaran, Michael E Belloy, Dolly Reyes-Dumeyer, Dörthe Jülich, Hüseyin Tayran, Elanur Yilmaz, Delaney Flaherty, Bengisu Turgutalp, Gauthaman Sukumar, Camille Alba, Elisa Martinez McGrath und 18 weitere

Acta Neuropathologica · 2024-06 · 147 (1)

DOI: 10.1007/s00401-024-02721-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropathologica, online erschienen am 10.04.2024. Verfasst von Prabesh Bhattarai und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Columbia University Irving Medical Center, Columbia University New York, New York, NY, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Fibronectins. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIGMS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The risk of developing Alzheimer’s disease (AD) significantly increases in individuals carrying the APOEε4 allele. Elderly cognitively healthy individuals with APOEε4 also exist, suggesting the presence of cellular mechanisms that counteract the pathological effects of APOEε4 ; however, these mechanisms are unknown. We hypothesized that APOEε4 carriers without dementia might carry genetic variations that could protect them from developing APOEε4- mediated AD pathology. To test this, we leveraged whole-genome sequencing (WGS) data in the National Institute on Aging Alzheimer's Disease Family Based Study (NIA-AD FBS), Washington Heights/Inwood Columbia Aging Project (WHICAP), and Estudio Familiar de Influencia Genetica en Alzheimer (EFIGA) cohorts and identified potentially protective variants segregating exclusively among unaffected APOEε4 carriers. In homozygous unaffected carriers above 70 years old, we identified 510 rare coding variants. Pathway analysis of the genes harboring these variants showed significant enrichment in extracellular matrix (ECM)-related processes, suggesting protective effects of functional modifications in ECM proteins. We prioritized two genes that were highly represented in the ECM-related gene ontology terms, (FN1) and collagen type VI alpha 2 chain ( COL6A2 ) and are known to be expressed at the blood–brain barrier (BBB), for postmortem validation and in vivo functional studies. An independent analysis in a large cohort of 7185 APOEε4 homozygous carriers found that rs140926439 variant in FN1 was protective of AD (OR = 0.29; 95% CI [0.11, 0.78], P = 0.014) and delayed age at onset of disease by 3.37 years (95% CI [0.42, 6.32], P = 0.025). The FN1 and COL6A2 protein levels were increased at the BBB in APOEε4 carriers with AD. Brain expression of cognitively unaffected homozygous APOEε4 carriers had significantly lower FN1 deposition and less reactive gliosis compared to homozygous APOEε4 carriers with AD, suggesting that FN1 might be a downstream driver of APOEε4 -mediated AD-related pathology and cognitive decline. To validate our findings, we used zebrafish models with loss-of-function (LOF) mutations in fn1b —the ortholog for human FN1 . We found that fibronectin LOF reduced gliosis, enhanced gliovascular remodeling, and potentiated the microglial response, suggesting that pathological accumulation of FN1 could impair toxic protein clearance, which is ameliorated with FN1 LOF. Our study suggests that vascular deposition of FN1 is related to the pathogenicity of APOEε4 , and LOF variants in FN1 may reduce APOEε4 -related AD risk, providing novel clues to potential therapeutic interventions targeting the ECM to mitigate AD risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseFibronectinsAgedAnimalsHumansGenetic VariationGliosisZebrafishApolipoproteins E

Substanzen

FibronectinsApoE protein, humanApolipoproteins EFN1 protein, human

Autor:innen und Institutionen

  • Department of Neurology, Columbia University Irving Medical Center, Columbia University New York, New York, NY, USA.
  • Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, Columbia University, New York, NY, USA.
  • Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
  • Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.
  • NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA.
  • Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.

ORCID-Profile: Caghan Kizil

Förderung

  • NIA NIH HHS
  • NIGMS NIH HHS
  • NIH HHS
  • National Institute on Aging

Zitieren

APA

Bhattarai, P., Gunasekaran, T. I., Belloy, M. E., Reyes-Dumeyer, D., Jülich, D., Tayran, H., Yilmaz, E., Flaherty, D., Turgutalp, B., Sukumar, G., Alba, C., McGrath, E. M., Hupalo, D. N., Bacikova, D., Le Guen, Y., Lantigua, R., Medrano, M., Rivera, D., Recio, P., …, & Vardarajan, B. N. (2024). Rare genetic variation in fibronectin 1 (FN1) protects against APOEε4 in Alzheimer’s disease. Acta Neuropathologica, 147(1). https://doi.org/10.1007/s00401-024-02721-1

Vancouver

Bhattarai P, Gunasekaran TI, Belloy ME, Reyes-Dumeyer D, Jülich D, Tayran H, et al. Rare genetic variation in fibronectin 1 (FN1) protects against APOEε4 in Alzheimer’s disease. Acta Neuropathologica. 2024;147(1). doi:10.1007/s00401-024-02721-1

BibTeX
@article{Bhattarai2024,
  author = {Bhattarai, Prabesh and Gunasekaran, Tamil Iniyan and Belloy, Michael E and Reyes-Dumeyer, Dolly and Jülich, Dörthe and Tayran, Hüseyin and Yilmaz, Elanur and Flaherty, Delaney and Turgutalp, Bengisu and Sukumar, Gauthaman and Alba, Camille and McGrath, Elisa Martinez and Hupalo, Daniel N and Bacikova, Dagmar and Le Guen, Yann and Lantigua, Rafael and Medrano, Martin and Rivera, Diones and Recio, Patricia and Nuriel, Tal and Ertekin-Taner, Nilüfer and Teich, Andrew F and Dickson, Dennis W and Holley, Scott and Greicius, Michael and Dalgard, Clifton L and Zody, Michael and Mayeux, Richard and Kizil, Caghan and Vardarajan, Badri N},
  title = {Rare genetic variation in fibronectin 1 (FN1) protects against APOEε4 in Alzheimer’s disease},
  journal = {Acta Neuropathologica},
  year = {2024},
  volume = {147},
  number = {1},
  doi = {10.1007/s00401-024-02721-1}
}
Kostenlos starten →